argenx SE (NASDAQ:ARGX) is reporting third quarter financial results on Thursday 22nd October 2020, before market open.
According to analysts surveyed by Thomson Reuters, ARGX is expected to report 3Q20 loss of $ 2.82 per share from revenue of $ 16.85 million.
For the full year, analysts anticipate top line of $ 81.97 million, while looking forward to loss of $ 11.22 per share bottom line.
Previous Quarter Performance
argenx SE posted loss for the second quarter of $ 3.15 per share, from the revenue of $ 3.54 million. Wall street analysts are predicting, ARGX to report 2Q20 loss of $ 2.74 per share from revenue of $ 22.51 million. The bottom line results missed street analysts by $ 0.41 or 14.96 percent, at the same time, top line results fell short of analysts by $ 18.97 million or 84.27 percent.
Stock Performance
Shares of argenx SE traded low $ -3.18 or -1.21 percent on Wednesday, reaching $ 259.37 with volume of 71.40 thousand shares. The stock opened down for the day at $ 261.23, after closing the previous day trading at $ 262.55.
According to the previous trading day, closing price of $ 262.55, representing a 153.06 % increase from the 52 week low of $ 103.75 and a 7.55 % decrease over the 52 week high of $ 284.00.
The company has a market capital of $ 12.21 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 6th October 2020, maintained by Bank of America at Buy rating, with $ 298.00 target price.
- On 5th October 2020, maintained by JMP Securities at Outperform rating, with $ 271.00 target price.
- On 30th September 2020, maintained by Piper Sandler at Overweight rating, with $ 300.00 target price.
- On 25th August 2020, initiated by Raymond James at Outperform rating, with $ 257.00 target price.
Conference Call
argenx SE will be hosting a conference call at 8:30 AM eastern time on 22nd October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.argenx.com
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis.
